INVITRO AND INVIVO EFFECTS OF MDP-LYS(L18) ON MOUSE MEGAKARYOCYTE PROGENITOR CELLS (CFU-MEG)

被引:0
|
作者
KOMIYA, I
KURIYA, S
AKAHANE, K
NOMURA, T
机构
[1] DAIICHI PHARMACEUT CO,RES INST,TOKYO,JAPAN
[2] NIPPON MED COLL,DEPT INTERNAL MED 3,TOKYO 113,JAPAN
[3] IWATE MED UNIV,DEPT INTERNAL MED 3,MORIOKA,IWATE 020,JAPAN
关键词
MDP-LYS(L18); MOUSE CFU-MEG; COLONY-STIMULATING ACTIVITY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We investigated the in vitro and in vivo effects of MDP-Lys(L18), a derivative of muramyl dipeptide (MDP), on megakaryocyte progenitor cells (megakaryocyte colony-forming units, CFU-Meg) in the mouse bone marrow and spleen. When CFU-Meg culture was performed with a suboptimum concentration (2%) of pokeweed mitogen-stimulated mouse spleen-conditioned medium (PWM-SCM), addition of 0.1-20-mu-g/ml of MDP-Lys(L18) increased the number of megakaryocyte colonies. The size of the megakaryocyte colonies (the number of megakaryocytes per colony) was also significantly increased by the addition of MDP-Lys(L18) under the same culture conditions in comparison with cultures without MDP-Lys(L18). MDP-Lys(L18) itself did not stimulate megakaryocyte colony formation without PWM-SCM, and it failed to enhance megakaryocyte colony formation in cultures with an optimum PWM-SCM concentration (10%). Furthermore, no effect of MDP-Lys(L18) was observed in cultures of phagocytic cell-depleted bone marrow cells. However, MDP-Lys(L18) enhanced megakaryocyte colony formation in cultures of T-lymphocyte-depleted bone marrow cells. The culture supernatant from a macrophage cell line, J774.1, plus MDP-Lys(L18) enhanced in vitro megakaryocyte colony formation in cultures with a suboptimum PWM-SCM concentration. Although interleukin 1 (IL-1)beta in the culture supernatant of J774.1 plus MDP-Lys(L18) was increased in a dose-dependent manner in response to MDP-Lys(L18), the effect of the culture supernatant was not blocked by an anti-IL-1 antibody, and IL-1-beta failed to enhance megakaryocyte colony formation in the presence of suboptimum PWM-SCM levels. The enhancement of megakaryocyte colony formation by MDP-Lys(L18) could be neutralized, however, by an anti-interleukin 6 (IL-6) antibody. Intraperitoneal administration of MDP-Lys(L18) (100-mu-g daily for 3 days) significantly increased the number of bone marrow and spleen megakaryocyte colonies at 24 to 72 h after the final injection. These in vitro and in vivo observations strongly suggest that MDP-Lys(L18) indirectly enhances the proliferation and differentiation of mouse CFU-Meg via colony-stimulating factor(s) other than IL-1, probably as a result of the stimulation of macrophages to produce IL-6.
引用
收藏
页码:517 / 522
页数:6
相关论文
共 19 条
  • [1] 3 STAGES OF DIFFERENTIATION IN MOUSE MEGAKARYOCYTE PROGENITOR CELLS (CFU-MEG)
    KURIYA, S
    OGATA, K
    YAMADA, T
    GOMI, S
    NOMURA, T
    [J]. EXPERIMENTAL HEMATOLOGY, 1990, 18 (05) : 416 - 420
  • [2] Ex vivo expansion of human megakaryocyte (MEG) progenitor cells (CFU-MEG).
    Ratajczak, J
    Ratajczak, MZ
    Gewirtz, AM
    [J]. BLOOD, 1995, 86 (10) : 1440 - 1440
  • [3] AUGMENTATION OF IMMUNE-RESPONSES BY A MURAMYL DIPEPTIDE ANALOG, MDP-LYS(L18)
    AKASAKI, M
    TAKASHI, T
    KITA, Y
    TSUKADA, W
    [J]. AGENTS AND ACTIONS, 1987, 22 (1-2): : 144 - 150
  • [4] RESTORATION BY MDP-LYS(L18) OF RESISTANCE TO PSEUDOMONAS PNEUMONIA IN IMMUNOSUPPRESSED GUINEA-PIGS
    OTANI, T
    KATAMI, K
    UNE, T
    OSADA, Y
    OGAWA, H
    [J]. MICROBIOLOGY AND IMMUNOLOGY, 1984, 28 (09) : 1077 - 1082
  • [5] Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus
    Fukushima, A
    Yoo, YC
    Yoshimatsu, K
    Matsuzawa, K
    Tamura, M
    Tonooka, S
    Taniguchi, K
    Urasawa, S
    Arikawa, J
    Azuma, I
    [J]. VACCINE, 1996, 14 (06) : 485 - 491
  • [6] PROTECTIVE EFFECT OF MDP-LYS(L18), A SYNTHETIC DERIVATIVE OF MURAMYLDIPEPTIDE, ON MURINE CYTOMEGALOVIRUS-INFECTION
    EIZURU, Y
    NAKAGAWA, N
    HAMASUNA, R
    MINAMISHIMA, Y
    [J]. NATURAL IMMUNITY, 1992, 11 (04) : 225 - 236
  • [7] MDP-Lys (L18), a synthetic muramyl dipeptide derivative, enhances antitumor activity of an inactivated tumor vaccine
    Yoo, YC
    Park, SY
    Lee, KB
    Azuma, I
    [J]. JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2000, 10 (03) : 399 - 404
  • [8] EFFECT OF MDP-LYS(L18), A DERIVATIVE OF MDP, ON ENHANCING HOST-RESISTANCE AGAINST HANTAAN VIRUS-INFECTION IN NEWBORN MICE
    YOO, YC
    YOSHIMATSU, K
    HATSUSE, R
    TAMURA, M
    YOSHIDA, R
    TONOOKA, S
    ARIKAWA, J
    AZUMA, I
    [J]. VACCINE, 1995, 13 (14) : 1300 - 1305
  • [9] Intrapleural therapy with MDP-Lys (L18), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer
    Yanagawa, H
    Haku, T
    Takeuchi, E
    Suzuki, Y
    Nokihara, H
    Sone, S
    [J]. LUNG CANCER, 2000, 27 (02) : 67 - 73
  • [10] MDP-LYS(L18), A LIPOPHILIC DERIVATIVE OF MURAMYL DIPEPTIDE, INHIBITS THE METASTASIS OF HEMATOGENOUS AND NON-HEMATOGENOUS TUMORS IN MICE
    YOO, YC
    SAIKI, I
    SATO, K
    AZUMA, I
    [J]. VACCINE, 1994, 12 (02) : 175 - 180